Moreover, in the phase 1 study NCT02013219, EGFR-mutated NSCLC patients received erlotinib (150 mg QD for 7 days), followed by erlotinib (150 mg QD) plus 1200 mg atezolizumab (1200 mg, q3w) [190]. Here, EGFR is linked to non-small cell lung carcinoma.